U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.
You may also be interested in...
Reinventing Cell Therapy And Biomaterials
A profound redefinition of the role of many cell types and biomaterials in regenerative medicine is under way as researchers have moved away from the notion that cells introduced into the body will integrate and become functioning tissue.
Cell-Therapy Deals A "Strategic Priority" For Shire
Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.
Cell-Therapy Deals A "Strategic Priority" For Shire
Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.